Gentium S.p.A. (NASDAQ: GENT), a biopharmaceutical company, specializes in discovering, researching, developing and manufacturing active ingredients derived from natural sources as potential therapeutic agents. The company focuses on developing relationships with industrial and academic institutions and intends to discover further beneficial effects of its products as well as develop pharmaceuticals with a broader range of treatment indications. For further information, visit the Company’s web site at http://www.gentium.com.
- 17 years ago
QualityStocks
Gentium S.p.A. (NASDAQ: GENT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Brazil Potash Corp. (NYSE-American: GRO) CEO To Speak At IDB Annual Meeting On Global Food Security
Brazil Potash (NYSE-American: GRO) announced that CEO Matt Simpson has been invited to participate as…
-
QualityStocksNewsBreaks – Perpetuals.com Ltd. (NASDAQ: PDC) CEO To Present At Emerging Growth Conference
Perpetuals.com (NASDAQ: PDC) announced that CEO Patrick Gruhn will present and host a live question-and-answer session…
-
QualityStocksNewsBreaks – Pelican Acquisition Corp. (NASDAQ: PELI) Approves Business Combination With Greenland Exploration And Pelican Holdco
Pelican Acquisition (NASDAQ: PELI) announced that shareholders approved its proposed business combination with Pelican Holdco…